---
title: "From the Era of Expansion to the Era of Efficiency: EC Healthcare Stands at the Crossroads of Consumer Healthcare Repricing"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42310259.md"
description: "On June 25, EC Healthcare issued a profit warning; on June 29, the company's board of directors reviewed the full-year results for the year ending March 31, 2026, and the final dividend. This annual report itself is just a corporate annual report card, but due to a profit warning, it has been placed in the context of a revaluation of the entire industry. According to the company's previous disclosure, the estimated revenue for the 2026 fiscal year is approximately 3.7 billion HKD, lower than the 4.14 billion HKD of the previous fiscal year; the estimated EBITDA loss is approximately 80 million to 110 million HKD..."
datetime: "2026-06-30T08:51:51.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42310259.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42310259.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42310259.md)
author: "[财报信号站](https://longbridge.com/en/profiles/2152743.md)"
---

# From the Era of Expansion to the Era of Efficiency: EC Healthcare Stands at the Crossroads of Consumer Healthcare Repricing

On June 25, Medical and Health Care (MHC) issued a profit warning; on June 29, the company's board of directors reviewed the full-year results and final dividend for the year ending March 31, 2026.

This annual report itself is just a corporate annual report card, but due to a profit warning, it has been placed in the context of the entire industry's revaluation.

According to the company's previous disclosure, revenue for the 2026 fiscal year is estimated to be approximately HK$3.7 billion, lower than the previous fiscal year's HK$4.14 billion; estimated EBITDA loss is approximately HK$80 million to HK$110 million, adjusted EBITDA is approximately HK$260 million to HK$290 million, and loss attributable to equity holders is approximately HK$380 million to HK$420 million. The company also emphasized that most of the impairment is non-cash items, and as of the end of March 2026, cash and bank balances, time deposits, and capital-protected notes are estimated to be approximately HK$945 million.

Looking solely at the disclosed data, the situation is not optimistic. However, when viewed within the entire development cycle of the company, it becomes apparent that it is more like a phased review of the consumer healthcare industry. In this context, how much MHC lost this year seems less important; what is important is which stage the entire consumer healthcare industry has entered.

**Industry competition has shifted from grabbing customers to a contest of operational efficiency**

The intersection of consumption upgrade and medical services has been an important label for the consumer healthcare sector. On this basis, almost all sub-sectors such as aesthetic medicine, dentistry, health check-ups, assisted reproduction, and high-end specialties have enjoyed valuation premiums. At this stage, the market focused on the number of clinics, brand matrix, member scale, and the speed of mergers and acquisitions.

More importantly, the growth logic of this stage was based on three common assumptions. First, the continuous expansion of the middle- and high-income group. Second, the continuous upgrade of medical consumption towards quality. Third, the more clinics and stronger brands, the faster the revenue growth.

But now, institutions are starting to recalculate per-clinic output, operating cash flow, doctor efficiency, customer repurchase rate, depreciation pressure, and capital expenditure payback period. In this context, although consumer healthcare remains a growth industry, the capital market is no longer willing to pay a growth premium just for the phrase "medical + consumption." The growth model of consumer healthcare is also shifting from relying on demand expansion to relying on operational optimization.

In the coming years, the consumer healthcare industry is likely to experience a new wave of consolidation. Many companies that rely on marketing-driven growth, price competition, and rapid expansion will continue to face profit pressure. Platforms that truly possess brand power, doctor resources, membership systems, and cash flow advantages will have the opportunity to regain valuation repair.

At the same time, capital market expectations for consumer healthcare are also changing: from discussing how many times PE should be, it will gradually shift to discussing operating cash flow, ROIC, free cash flow, and return on capital.

Consumer healthcare will start to look more and more like a service company. This change will continue to affect the valuation system of the entire Hong Kong stock healthcare services sector in the coming years.

The main capital story for MHC in the future is precisely about the improvement of operational efficiency.

**MHC has already written this change into its income statement**

MHC has continuously covered various fields such as dentistry, health check-ups, aesthetic medicine, specialty medicine, and veterinary medicine through mergers and acquisitions, hoping to build a one-stop healthcare platform. From a revenue perspective, this model was once very successful, with revenue maintaining growth for many consecutive years, and the market also gave it a high valuation.

However, the demand side is not very optimistic. Since 2025, the recovery speed of local consumption in Hong Kong has significantly slowed, and residents have become more cautious in their spending. Although mainland consumption in Hong Kong still exists, the structure has changed. The recovery speed of high-ticket projects is significantly slower than expected, and value for money has become something the public pays more attention to.

This change directly affects consumer healthcare. Aesthetic medicine projects are more susceptible to price competition; dental treatment is returning to basic treatments; health check-ups are paying more attention to package prices; specialty medicine relies more on doctor resources and brand reputation. The model of relying on marketing to drive growth is slowly reaching its ceiling.

MHC's interim data for the 2026 fiscal year has already released this signal in advance. Medical business revenue decreased by more than 14% year-on-year, while aesthetic medicine and health business maintained single-digit growth.

This means that a new differentiation is beginning to appear within the industry. Not all consumer healthcare demand is declining; it's just that the recovery speed of different businesses is completely different. For example, businesses with higher repurchase rates, more stable demand, and better cash flow, such as chronic disease management, home healthcare, health management, and continuous health check-ups, may have relatively slower growth rates, but they possess higher customer lifetime value.

The capital market has begun to accept the decline in revenue growth rate, but the continuous decline in profit margin is still a situation that the market cannot accept and is closely monitoring. Indicators such as operating profit margin, operating cash flow, per-clinic profitability, and member repurchase rate are becoming new valuation anchors.

**The impairment in the income statement is more worthy of analysis than the profit figure**

Regarding MHC's profit warning this time, the public can easily focus on the expanded loss, but what is worth dissecting is the source of the loss.

The announcement shows that the company expects to recognize a large amount of goodwill and intangible asset impairment, as well as impacts from property, equipment, other receivables, and changes in the fair value of financial assets.

The capital market has always had two completely different understandings of impairment.

One believes it is a deterioration in operations. The other believes it is a one-time release of historical burdens. The difference lies in whether the operations themselves continue to generate cash. If the main business deteriorates simultaneously, then impairment is just the result. If the main business can still maintain cash flow, then impairment is more about the repricing of the balance sheet.

Therefore, Adjusted EBITDA is more important than EBITDA.

MHC expects adjusted EBITDA for the 2026 fiscal year to still be HK$260 million to HK$290 million. Although this is a decrease compared to the previous year's HK$375 million, its impact on the overall situation is not significant. What it should really be wary of is that after consumer demand slows down, the large amount of assets formed during the high valuation period needs to be recalculated for how much profit they can generate in the future.

The consumer healthcare industry previously grew significantly through mergers and acquisitions, which implies goodwill. But once demand declines, goodwill will also begin to be impaired. This logic does not only apply to MHC. In the coming years, the entire consumer healthcare industry may enter an asset repricing cycle.

Therefore, the public should focus on several more critical questions. Has revenue begun to stabilize? Is operating cash flow still healthy? Has capital expenditure decreased? Has per-clinic efficiency improved? And these indicators determine profitability in the next two or three years, not this year's profit.

In addition, there is another easily overlooked but very important signal: the final dividend. Consumer healthcare has always had relatively stable cash flow, so many institutional funds view it as a consumer asset with both growth and dividend attributes. If dividend-paying ability continues to decline, it means cash flow is beginning to bear more operational pressure; if the company can still maintain a certain level of dividend distribution, it indicates that the board of directors still has confidence in its cash-generating ability.

### Related Stocks

- [02138.HK](https://longbridge.com/en/quote/02138.HK.md)